1. Introduction {#sec1-pharmacy-05-00028}
===============

Suboptimal choice of outcomes to assess health care interventions may result in lack of implementation of potentially effective interventions, which could have benefitted the care of patients.

Traditionally, new interventions and services in health care have been implemented if they seemed reasonable, but in recent times with scarce resources, documentation of (cost) effect is essential before implementing a new service. Clinical pharmacy services, including medication reviews, are among many other interventions exposed to documentation of the suggested effect, and indeed, systematic reviews have found some effect of clinical pharmacist interventions in inpatient care \[[@B1-pharmacy-05-00028],[@B2-pharmacy-05-00028],[@B3-pharmacy-05-00028],[@B4-pharmacy-05-00028],[@B5-pharmacy-05-00028]\]. However, evaluation of clinical pharmacy services is challenging due to the interventions often being complex and non-specific, and the purpose is often to optimise the use of medications, reduce medication-related risks and improve symptom control \[[@B6-pharmacy-05-00028],[@B7-pharmacy-05-00028]\]. Consequently, choice of outcome measures is difficult.

However, choice of outcomes is not the only challenge when conducting outcome research; other essential components include quality of the study, study design, type of intervention, the patient population, etc. \[[@B8-pharmacy-05-00028]\]. The Donabedian framework is frequently used to evaluate clinical pharmacy services. The model consists of three elements; structure, process and outcome. Structure is the context in which the intervention is delivered, process describes the actions that make up the intervention, and outcomes refers to the effects of the intervention on health status of patients and populations \[[@B9-pharmacy-05-00028],[@B10-pharmacy-05-00028]\]. However, most attention is usually given to outcome measures \[[@B8-pharmacy-05-00028],[@B11-pharmacy-05-00028],[@B12-pharmacy-05-00028]\].

Outcomes can be categorized into "hard" endpoints, such as mortality and hospital admissions, and "soft" endpoints, such as quality of life, drug-related problems and patient satisfaction. It has been argued that it is essential to select outcomes on which the intervention is likely to have an effect, and that hard endpoints may not be optimal outcome measures, because clinical pharmacy interventions are unlikely to result in changes in these measures \[[@B7-pharmacy-05-00028],[@B8-pharmacy-05-00028]\]. In addition, it is essential that a sufficient number of patients are included in the studies (sample size), and a proper power calculation has been performed to ensure knowledge of the minimum number of patients required to detect statistical significance \[[@B13-pharmacy-05-00028]\]. However, previously no review of the literature has been conducted with the main aim to describe clinical outcomes used in clinical pharmacy intervention studies including the related results reported.

The aim was to investigate type, frequency and result of clinical outcomes used in studies to assess the effect of clinical pharmacy interventions in inpatient care.

2. Materials and Methods {#sec2-pharmacy-05-00028}
========================

2.1. Search Strategy {#sec2dot1-pharmacy-05-00028}
--------------------

When conducting our literature search, we sought to identify intervention studies performed by clinical pharmacists, which had been evaluated using clinical outcome measures. A literature search was performed using the search phrases: "Intervention(s)" and "pharmacist(s)" and "controlled" and "outcome(s)" or "effect(s)".

Publications were included if they:described primary researchwere published in Englishdescribed interventions delivered by clinical pharmacists

Publications were excluded if they:were not published as a research paper (e.g., reviews, books, congress abstracts, posters, reports, protocols)did not include outcome datapresented data for a secondary study, where the original study had been published previouslyhad been conducted in primary careincluded 100 patients or less

The search was performed for the period up to 2013 using PubMed (TRHN).

2.2. Assessment {#sec2dot2-pharmacy-05-00028}
---------------

All titles and publication types from the original search were reviewed independently by TRHN and LJK. Subsequently, abstracts were reviewed by the two authors. Thereafter, full-text articles were reviewed independently by CO and LJK. Finally, CO and LJK extracted data form the studies independently. At every step, disagreements were resolved by consensus. The data extracted were details regarding the study, the intervention, outcomes and power calculation.

For each included study, the variable used for power calculation was categorized as "primary outcome" irrespective of whether it was stated to be the "primary outcome" by the authors. Also, when more than one variable was stated to be "primary outcome" by the authors, only variables supported by power calculations were categorized as "primary outcome". In contrast, if no power calculation was presented and no primary endpoint was stated, all outcomes were categorized as "secondary outcomes" irrespective of the authors stating otherwise.

Some measures were excluded due to assessing qualitative aspects or being descriptive: Number of drugs, drug-related problems (DRPs), acceptance rates, medication knowledge if not assessed using a validated tool, drug burden index, inhalation technique, medication errors unless linked to an event/clinical assessment, drug attitude, quality of well-being, appropriateness of prescribing of individual drugs, self-reported asthma symptoms.

3. Results {#sec3-pharmacy-05-00028}
==========

3.1. Study Selection {#sec3dot1-pharmacy-05-00028}
--------------------

A total of 672 studies were identified in the PubMed search ([Figure 1](#pharmacy-05-00028-f001){ref-type="fig"}). After removing 11 papers due to duplicate publication and non-English language, in- and exclusion criteria were applied to 661 unique publication titles and subsequently to 432 unique abstracts ([Figure 1](#pharmacy-05-00028-f001){ref-type="fig"}). Of these, 241 full-text publications were reviewed, and 204 were excluded due to: Study conducted in primary care (*n* = 90), outcomes not clearly presented (*n* = 7), ≤100 pts (*n* = 98), and secondary article (*n* = 9). Finally, 37 unique publications were included in the review \[[@B14-pharmacy-05-00028],[@B15-pharmacy-05-00028],[@B16-pharmacy-05-00028],[@B17-pharmacy-05-00028],[@B18-pharmacy-05-00028],[@B19-pharmacy-05-00028],[@B20-pharmacy-05-00028],[@B21-pharmacy-05-00028],[@B22-pharmacy-05-00028],[@B23-pharmacy-05-00028],[@B24-pharmacy-05-00028],[@B25-pharmacy-05-00028],[@B26-pharmacy-05-00028],[@B27-pharmacy-05-00028],[@B28-pharmacy-05-00028],[@B29-pharmacy-05-00028],[@B30-pharmacy-05-00028],[@B31-pharmacy-05-00028],[@B32-pharmacy-05-00028],[@B33-pharmacy-05-00028],[@B34-pharmacy-05-00028],[@B35-pharmacy-05-00028],[@B36-pharmacy-05-00028],[@B37-pharmacy-05-00028],[@B38-pharmacy-05-00028],[@B39-pharmacy-05-00028],[@B40-pharmacy-05-00028],[@B41-pharmacy-05-00028],[@B42-pharmacy-05-00028],[@B43-pharmacy-05-00028],[@B44-pharmacy-05-00028],[@B45-pharmacy-05-00028],[@B46-pharmacy-05-00028],[@B47-pharmacy-05-00028],[@B48-pharmacy-05-00028],[@B49-pharmacy-05-00028],[@B50-pharmacy-05-00028]\]. Two publications were based on one study, but since different outcome measures were presented in the respective papers, both were included \[[@B33-pharmacy-05-00028],[@B34-pharmacy-05-00028]\].

3.2. Description of Studies {#sec3dot2-pharmacy-05-00028}
---------------------------

The included studies had been conducted in 16 countries in Europe, Asia, Australasia, Middle East and North America, and most frequently in the US with ten studies ([Table 1](#pharmacy-05-00028-t001){ref-type="table"}). The majority of the studies had been conducted at one hospital (*n* = 30), but four studies included patients from three hospitals and one from 10 hospitals ([Table 1](#pharmacy-05-00028-t001){ref-type="table"}). Number of patients included in the study ranged from 105 to 4290 ([Table 1](#pharmacy-05-00028-t001){ref-type="table"}). The type of wards and study populations varied considerably, but the majority included patients were suffering from a chronic disease ([Table 1](#pharmacy-05-00028-t001){ref-type="table"}).

A traditional randomized, controlled design was applied for the majority (*n* = 26) of the studies ([Table 2](#pharmacy-05-00028-t002){ref-type="table"}). The interventions provided appeared similar but differed in types of elements. However, more than half of the studies (*n* = 20) included a combination of patient counselling, medication review and interdisciplinary collaboration ([Table 2](#pharmacy-05-00028-t002){ref-type="table"}). Only two studies were finalised with no further follow up at discharge \[[@B38-pharmacy-05-00028],[@B48-pharmacy-05-00028]\] ([Table 2](#pharmacy-05-00028-t002){ref-type="table"}). All other studies presented interventions which included post-discharge contact with health care professionals or follow-up for effect evaluation---or both---and two studies described interventions with a duration of two years \[[@B20-pharmacy-05-00028],[@B49-pharmacy-05-00028]\].

3.3. Description of Outcome {#sec3dot3-pharmacy-05-00028}
---------------------------

The included studies used a plethora (135) of outcome measures to evaluate their interventions ranging from two \[[@B15-pharmacy-05-00028],[@B46-pharmacy-05-00028]\] to 13 \[[@B14-pharmacy-05-00028]\] ([Table 3](#pharmacy-05-00028-t003){ref-type="table"}). The most prevalent measures included laboratory measures, clinical measures/assessments by physician and health care service use, however, a large variety of measures within the categories were used. A mixture of generic and disease specific measures was reported ([Table 3](#pharmacy-05-00028-t003){ref-type="table"}). Examples of generic measures include medication adherence assessed by the 4-item Morisky Scale, health-related quality of life assessed by SF-36, and service use assessed by LOS in hospital. Examples of disease specific measures comprise knowledge assessed by Malaysian Osteoporosis Knowledge Tool (MOKT), health-related quality of life assessed by QUALEFFO and service use assessed by Number of CHF hospitalizations within 6 months of enrollment.

Some of the studies had selected a primary outcome measure directly related to medication use and knowledge \[[@B21-pharmacy-05-00028],[@B32-pharmacy-05-00028],[@B34-pharmacy-05-00028],[@B36-pharmacy-05-00028],[@B41-pharmacy-05-00028],[@B44-pharmacy-05-00028],[@B45-pharmacy-05-00028],[@B47-pharmacy-05-00028],[@B50-pharmacy-05-00028]\], while others chose measures which may be consequences of the interventions (e.g., laboratory tests, hospital readmission and mortality \[[@B14-pharmacy-05-00028],[@B16-pharmacy-05-00028],[@B17-pharmacy-05-00028],[@B18-pharmacy-05-00028],[@B20-pharmacy-05-00028],[@B22-pharmacy-05-00028],[@B23-pharmacy-05-00028],[@B25-pharmacy-05-00028],[@B26-pharmacy-05-00028],[@B27-pharmacy-05-00028],[@B29-pharmacy-05-00028],[@B30-pharmacy-05-00028],[@B31-pharmacy-05-00028],[@B35-pharmacy-05-00028],[@B38-pharmacy-05-00028],[@B40-pharmacy-05-00028],[@B41-pharmacy-05-00028],[@B42-pharmacy-05-00028],[@B43-pharmacy-05-00028],[@B49-pharmacy-05-00028]\]). Adherence, HbA1c values, LDL values, emergency department visits, and hospital readmission were used as primary as well as secondary outcomes.

No apparent pattern was established among primary outcome measures with significant effect in favour of the intervention.

More than half (*n* = 21) of the studies did not present any power calculation (*n* = 13) or did not include sufficient patients according to their power calculation (*n* = 8) ([Table 3](#pharmacy-05-00028-t003){ref-type="table"}). Of the 26 primary outcome measures showing a statistically significant effect, 73% reported a power calculation and included sufficient patients according to the power calculation. Only 25% of the 16 primary outcome measures with no statistically significant effect reported a power calculation and included a sufficient number of patients ([Table 3](#pharmacy-05-00028-t003){ref-type="table"}).

4. Discussion {#sec4-pharmacy-05-00028}
=============

The literature review included 37 publications worldwide describing quite similar intervention elements but differing in study design. A large variety of outcome measures had been used to evaluate the effect of the interventions; most frequently clinical measures/assessments by physicians and health care service use. No apparent pattern was established among primary outcome measures with significant effect in favour of the intervention, but positive effect was most frequently related to studies that included power calculations and sufficient inclusion of patients.

4.1. Outcome Measures {#sec4dot1-pharmacy-05-00028}
---------------------

The large variety of outcomes used in the included studies may be explained by the lack of consensus of optimal outcome measures for this type of intervention \[[@B11-pharmacy-05-00028],[@B12-pharmacy-05-00028]\].

4.2. Generic Versus Disease Specific Tools {#sec4dot2-pharmacy-05-00028}
------------------------------------------

Since the interventions are usually complex and the patient populations are often heterogeneous, optimal outcome measures to ensure comparison between studies should be generic. Indeed, numerous generic measures were included in the studies (e.g., adherence measures, ADEs, service use and HRQoL). However, diverging methods were used (e.g., for assessment of adherence (self-reported and objective)), a variety of elements were used (e.g., to assess ADEs (potential and preventable)), different time periods were used (e.g., for assessment of emergency department visits (3 days, 30 days 12 months)) and various tools were used (e.g., for assessment of HRQoL (SF 12, SF 36, self-rated global health)). Even if similar interventions are selected, comparison between the studies would be complicated by differences in type of outcome measure---and design, inclusion criteria, etc.

The large number of disease-specific tools reported as outcome measures may derive from an expectation of these being more relevant for the particular cohort (diversity of patients across studies)---and perhaps an expectation of these measures being more sensitive to change, than generic measures.

Mortality/survival was reported as outcome measures in six studies. The only study providing a power calculation and including sufficient patients showed a positive effect on "Time from randomization to death from any cause" \[[@B49-pharmacy-05-00028]\]. The continuous variable may be an easier way to evaluate a rare event such as mortality, which usually requires large sample sizes or long follow-up periods to ensure sufficient power \[[@B7-pharmacy-05-00028],[@B8-pharmacy-05-00028]\]. However, the aspect of time of follow up is important, since there is a risk of a short follow up resulting in insufficient data (few patients have died) as well as excessive (most patients have died), and this time period is likely to vary according to the characteristics of the included patients. This further complicates the comparison between studies. Hence, survival analysis may be the optimal measure for this outcome. When no effect on an outcome is found in studies with insufficient power, it may be interpreted as "evidence of absence" as in a Cochrane review, while the interpretation should be "absence of evidence" due to lack of power in the included studies \[[@B2-pharmacy-05-00028],[@B51-pharmacy-05-00028]\].

4.3. Primary Versus Secondary Outcomes {#sec4dot3-pharmacy-05-00028}
--------------------------------------

Primary outcomes are used to determine the effect of the intervention, while secondary outcomes evaluate additional effects of the intervention. However, power calculation is only done on primary outcome measures \[[@B13-pharmacy-05-00028]\]. The number of outcome measures used in the included studies varied considerably (2--13), which may be explained by different needs to determine additional effects of the individual interventions. Laboratory measures, clinical measures/assessments by physician and health care service use were prevalent measures, which may be explained by these measures often being documented as a part of routine patient assessment, and hence easy to collect. Still, they seem to be relevant outcome measures to assess the effect of the studies.

4.4. Target Groups for Results {#sec4dot4-pharmacy-05-00028}
------------------------------

Another reason for selecting several outcome measures may be the importance of evaluating the intervention with respect to different stakeholders. The importance of an effect may vary according to the perspective, (e.g., patient, care-givers, health care professionals, decision makers and researchers) may not agree on, which outcome measure is the most important \[[@B8-pharmacy-05-00028]\].

4.5. Relevant Outcomes {#sec4dot5-pharmacy-05-00028}
----------------------

Further discussions about which outcomes may be relevant to quantify the desired effects of clinical pharmacy interventions are needed. It is important to consider whether an effect can indeed be expected on the selected outcomes \[[@B8-pharmacy-05-00028],[@B11-pharmacy-05-00028],[@B12-pharmacy-05-00028]\]. New approaches to standardize outcome measures in clinical trials are emerging, and the results of this review confirm the need for a standard set of core outcome measures \[[@B11-pharmacy-05-00028],[@B12-pharmacy-05-00028]\]. If the aim of clinical pharmacist interventions is to improve symptom control, reduce medication-related risks, improve benefits of medication use and prevent development of conditions, it is possible that outcomes such as preventable adverse drug events, measures directly related to medication use and knowledge, and other soft endpoints are likely to be more appropriate than hard endpoints such as mortality and hospital readmission, since they measure aspects which may be affected by the interventions \[[@B8-pharmacy-05-00028]\]. A variety of these measures have been used as primary outcome measures in the included studies with varying results.

Finally, it should be kept in mind that even more outcomes may have been used to assess clinical pharmacy interventions, however, a publication bias may exist, which may have led to exclusion of some non-significant or negative outcomes.

4.6. Implementation Rate of the Clinical Pharmacy Intervention {#sec4dot6-pharmacy-05-00028}
--------------------------------------------------------------

Clinical pharmacy interventions usually include provision of professional knowledge to a team of health care professionals or directly to the patient \[[@B1-pharmacy-05-00028],[@B7-pharmacy-05-00028]\]. The processes involved when providing knowledge are quite complex, and consequently it is often difficult to measure the pharmacist's contribution to a multidisciplinary team \[[@B8-pharmacy-05-00028]\]. Hence, applying process measures as suggested by the Donabedian model is useful to document the tasks actually provided by the clinical pharmacist. Frequently used process measures include type and number of drug-related problems (DRPs) identified, the acceptance rate of suggested recommendations made by the clinical pharmacist to address these DRPs, and implementation rates \[[@B1-pharmacy-05-00028]\]. However, the acceptance rates and implementation rates of suggested recommendations vary considerably between studies, with usually around 65--70% acceptance rates---but some as low as 40% \[[@B1-pharmacy-05-00028],[@B2-pharmacy-05-00028]\]. Whether low acceptance and implementation rates are due to suboptimal recommendations, barriers among physicians to accept and implement recommendations, or poor collaboration in the health care team remains unclear, and no suggestions of a minimum requirement for acceptance or implementation rates exist. This pose another challenge of interpreting outcomes, since studies with a sufficient number of included patients may not have had a proper exposure of the intervention to intervention patients. Consequently, the success of the clinical pharmacy intervention may be highly dependent on individual participants in the health care team, including the clinical pharmacist herself.

4.7. Limitation {#sec4dot7-pharmacy-05-00028}
---------------

Various methods exist to assess the quality of intervention studies (e.g., criteria developed by the Cochrane Effective Practice and Organisation of Care Review Group \[[@B52-pharmacy-05-00028]\]). No formal quality assessment of the included studies was performed in the present review due to the exploratory nature of the review, however, ensuring sufficient power in a study is essential to avoid Type II errors, and more than half of the studies either did not include sufficient patients according to their power calculation or the power calculation was missing. This risk of Type II errors complicates the assessment of the potential effect and relevance of the selected outcome variables \[[@B13-pharmacy-05-00028]\].

Types of statistical analyses used were not systematically collected. Comparison between studies may be further compromised, when different analyses are used i.e., continued variables (linear regression and ANOVA), binary outcomes (logistic regression), time to event (survival analysis), etc., since type of analysis is important for interpretation of the results.

Other aspect regarding the analyses, which was not systematically collected, were handling of dropouts and incomplete data (e.g., "last observation carried forward", exclusion, imputation, etc.) These may also affect the results and hence the interpretation of results differently.

Further, studies including 100 patients or less were excluded. It is likely that if they had been included, the proportion of studies with no reported power calculation and insufficient power may have been higher.

5. Conclusions {#sec5-pharmacy-05-00028}
==============

Type, frequency and result of clinical outcomes used to assess the effect of clinical pharmacy interventions in inpatient care varied considerably among the included studies. The most frequently reported outcome measures included clinical measures/assessments by physician and health care service use. No obvious pattern was established among primary outcome measures with significant effect in favour of the intervention, but positive effect was most frequently related to studies with presentation of power calculations and sufficient inclusion of patients. This review emphasizes the importance of considering the relevance of outcomes selected to assess clinical pharmacy interventions. Further discussion and consensus is needed with regard to selection of types of outcomes to ensure comparison of the effects among clinical pharmacy studies. Furthermore, conducting a proper power calculation and including the sufficient number of patients in the study according to the power calculation should be a prerequisite when publishing an outcome evaluation of clinical pharmacy intervention studies.

All authors have contributed to data evaluation of the study, and all authors have contributed to the manuscript. CO, TRHN and LJK did the study selection and data extraction, and LJK drafted the manuscript.

The authors declare no conflict of interest.
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pharmacy-05-00028-t001_Table 1

###### 

Description of the studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                      Setting and Country                                                                    Patient Population                                                                                                       No. of Included Patients   No. of Patients Analysed/at Endpoint       Mean Age (Years)\      Mean Age (Years)\        Gender, Male (%)\          Gender, Male (%)\
                                                                                                                                                                                                                                                                                                                                                    IG                     CG                       IG                         CG
  ----------------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ -------------------------- ------------------------------------------ ---------------------- ------------------------ -------------------------- ----------------------------
  Al Mazroui et al. (2009) \[[@B14-pharmacy-05-00028]\]       General medical wards, endocrinology and medical outpatient clinics, 1 Hospital, UAE   Pts with type 2 diabetes                                                                                                 240 pts:\                  234 pts:\                                  48.7, *n* = 120        49.9, *n* = 120          84 (70), *n* = 120         82 (68.3), *n* = 120
                                                                                                                                                                                                                                                                              IG: 120 pts\               IG: 117\                                                                                                              
                                                                                                                                                                                                                                                                              CG: 120 pts                CG: 117                                                                                                               

  Albsoul-Younes et al. (2011) \[[@B15-pharmacy-05-00028]\]   1 family medicine clinic, 1 hospital, Jordan                                           Pts with uncontrolled hypertension                                                                                       266 pts:\                  253 pts:\                                  56.3, *n* = 130        57.5, *n* = 123          61 (47), *n* = 130         59 (48), *n* = 123
                                                                                                                                                                                                                                                                              IG: 136 pts\               IG: 130 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 130 pts                CG: 123                                                                                                               

  Barker et al. (2012) \[[@B16-pharmacy-05-00028]\]           1 hospital, Australia                                                                  Pts with chronic heart failure                                                                                           120 pts:\                  87 pts:\                                   73.0, *n* = 64         72.0, *n* = 56           32 (50), *n* = 64          23 (41), *n* = 56
                                                                                                                                                                                                                                                                              IG = 64 pts\               IG: 48 pts\                                                                                                           
                                                                                                                                                                                                                                                                              CG = 56 pts                CG: 39 pts                                                                                                            

  Bladh et al. (2011) \[[@B17-pharmacy-05-00028]\]            2 internal medicine wards, 1 hospital, Sweden                                          All patients admitted to the wards on week days                                                                          400 pts:\                  345 pts:\                                  Median:\               Median:\                 ITT: 66 (40), *n* = 164\   ITT/PP: 71 (39), *n* = 181
                                                                                                                                                                                                                                                                              IG: 199 pts\               IG: 164\                                   ITT: 81, *n* = 164\    ITT/PP: 82, *n* = 181    PP: 30 (34), *n* = 87      
                                                                                                                                                                                                                                                                              CG: 201 pts                CG: 181                                    PP: 84, *n* = 87                                                           

  Chan et al. (2012) \[[@B18-pharmacy-05-00028]\]             1 diabetics clinic, 1 hospital, Hong Kong                                              Pts with type 2 diabetes                                                                                                 105 pts:\                  105 pts:\                                  63.2, *n* = 51         61.7, *n* = 54           30 (59), *n* = 51          28 (52), *n* = 54
                                                                                                                                                                                                                                                                              IG: 51 pts\                IG: 51 pts\                                                                                                           
                                                                                                                                                                                                                                                                              CG: 54 pts                 CG: 54 pts                                                                                                            

  Chiu et al. (2008) \[[@B19-pharmacy-05-00028]\]             Outpatients, 1 hospital, Taiwan                                                        Pts with ischemic stroke                                                                                                 160 pts:\                  Missing                                    65.7, *n* = 80         64.8, *n* = 80           40 (50), *n* = 80          40 (50), *n* = 80
                                                                                                                                                                                                                                                                              IG: 80 pts\                                                                                                                                      
                                                                                                                                                                                                                                                                              CG: 80 pts                                                                                                                                       

  Chung et al. (2011) \[[@B20-pharmacy-05-00028]\]            1 lipid clinic (medical outpatient), 1 hospital, Hong Kong                             Pts with chronic dyslipidaemia                                                                                           300 pts:\                  300 pts:\                                  56.2, *n* = 150        57.9, *n* = 150          68 (45), *n* = 150         60 (40), *n* = 150
                                                                                                                                                                                                                                                                              IG: 150 pts\               IG: 150 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 150 pts                CG: 150 pts                                                                                                           

  Crotty et al. (2004) \[[@B21-pharmacy-05-00028]\]           3 hospitals, Australia                                                                 Elderly pts awaiting transfer from hospital to a long term residential care facility for the first time                  110 pts:\                  88 pts:\                                   82.0                   83.4                     41%                        37%
                                                                                                                                                                                                                                                                              IG: 56 pts\                IG: 44 pts\                                                                                                           
                                                                                                                                                                                                                                                                              CG: 54 pts                 CG: 44                                                                                                                

  Dedhia et al. (2009) \[[@B22-pharmacy-05-00028]\]           General medicine wards, 3 hospitals, USA                                               Pts aged ≥65 years                                                                                                       422 pts:\                  422 pts:\                                  76.7                   77.3                     72 (39), *n* = 185         94 (40), *n* = 237
                                                                                                                                                                                                                                                                              IG: 185 pts\               IG: 185 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 237 pts                CG: 237 pts                                                                                                           

  Gillespie et al. (2009) \[[@B23-pharmacy-05-00028]\]        2 acute internal medicine wards, 1 hospital, Sweden                                    Pts admitted to the wards                                                                                                400 pts:\                  368 pts:\                                  86.4, *n* = 182        87.1, *n* = 186          77 (42), *n* = 182         75 (40) *n* = 186
                                                                                                                                                                                                                                                                              IG: 199 pts\               IG: 182 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 201 pts                CG: 186 pts                                                                                                           

  Hammad et al. (2011) \[[@B24-pharmacy-05-00028]\]           6 family medicine outpatient clinics, 1 Hospital, Jordan                               Pts with metabolic syndrome                                                                                              202 pts:\                  199 pts:\                                  56.0, *n* = 110        57.4, *n* = 89           44 (40), *n* = 110         32 (36), *n* = 89
                                                                                                                                                                                                                                                                              IG: 112 pts\               IG: 110 pt\                                                                                                           
                                                                                                                                                                                                                                                                              CG: 90 pts                 CG: 89 pts                                                                                                            

  Hellström et al. (2012) \[[@B25-pharmacy-05-00028]\]        3 internal medicine wards, 1 hospital, Sweden                                          All patients hospitalised at the three study wards                                                                       4290 pts:\                 3974 pts:\                                 78.3                   79.5                     46%                        45%
                                                                                                                                                                                                                                                                              IG: 1325\                  IG: 1216 pts\                                                                                                         
                                                                                                                                                                                                                                                                              CG: 2965                   CG: 2758                                                                                                              

  Jack et al. (2009) \[[@B26-pharmacy-05-00028]\]             1 hospital, USA (entire hospital)                                                      Pts admitted to the hospital, ≥18 years and English speaking                                                             749 pts:\                  738 pts:\                                  50.1, *n* = 373        49.6, *n* = 376          195 (52), *n* = 373        176 (47), *n* = 376
                                                                                                                                                                                                                                                                              IG: 373 pts\               IG: 370 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 376 pts                CG: 368 pts                                                                                                           

  Jackson et al. (2004) \[[@B27-pharmacy-05-00028]\]          1 hospital, Australia (entire hospital)                                                Pts initiated on warfarin in hospital                                                                                    128 pts:\                  127 pts:\                                  Median:\               Median: 72.5, *n* = 68   53%, *n* = 60              53%, *n* = 68
                                                                                                                                                                                                                                                                              IG: 60 pts\                IG: 59 pts\                                70, *n* = 60                                                               
                                                                                                                                                                                                                                                                              CG: 68 pts                 CG: 68 pts                                                                                                            

  Jacobs et al. (2012) \[[@B28-pharmacy-05-00028]\]           An ambulatory general internal medicine setting, 1 Clinic, USA                         Pts with type 2 diabetes                                                                                                 396 pts:\                  164 pts:\                                  62.7, *n* = 72         63.0, *n* = 92           49 (68), *n* = 72          51 (55), *n* = 92
                                                                                                                                                                                                                                                                              IG: 195 pts\               IG: 72 pts\                                                                                                           
                                                                                                                                                                                                                                                                              CG: 201 pts                CG: 92 pts                                                                                                            

  Jarab et al. (2012a) \[[@B29-pharmacy-05-00028]\]           1 outpatient COPD Clinic, 1 Hospital, Jordan                                           Pts with COPD                                                                                                            133 pts:\                  127 pts:\                                  Median:\               Median: 64, *n* = 67     26 (39), *n* = 66          28 (42), *n* = 67
                                                                                                                                                                                                                                                                              IG: 66 pts\                IG: 63 pts\                                61, *n* = 66                                                               
                                                                                                                                                                                                                                                                              CG: 67 pts                 CG: 64 pts                                                                                                            

  Jarab et al. (2012b) \[[@B30-pharmacy-05-00028]\]           outpatient diabetes clinic, 1 hospital, Jordan                                         Pts with type 2 diabetes                                                                                                 171 pts:\                  IG: 77 pts, CG: 79 pts                     63.4, *n* = 85         65.3, *n* = 86           68%, *n* = 85              56%, *n* = 86
                                                                                                                                                                                                                                                                              IG: 85 pts\                                                                                                                                      
                                                                                                                                                                                                                                                                              CG: 86 pts                                                                                                                                       

  Kirwin et al. (2010) \[[@B31-pharmacy-05-00028]\]           1 hospital-based, primary care practice, 1 hospital, USA                               Pts with diabetes (type 1 and 2)                                                                                         346 pts:\                  301 pts:\                                  62.9, *n* = 150        62.8, *n* = 151          29% *n* = 150              39% *n* = 151
                                                                                                                                                                                                                                                                              IG: 171 pts\               IG: 150 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 175 pts                CG: 151 pts                                                                                                           

  Kripalani et al. (2012) \[[@B32-pharmacy-05-00028]\]        2 medical centers, 2 hospitals, USA                                                    Pts with acute coronary syndromes or acute decompensated heart failure                                                   862 pts:\                  851 pts:\                                  61, *n* = 423          59, *n* = 428            250 (59), *n* = 423        249 (58), *n* = 428
                                                                                                                                                                                                                                                                              IG: 430 pts\               IG: 423 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 432 pts                CG: 428 pts                                                                                                           

  Lai et al. (2013) \[[@B33-pharmacy-05-00028]\]              1 osteoporosis clinic, 1 hospital, Malaysia                                            Pts with postmenopausal osteoporosis                                                                                     198 pts:\                  177\                                       65.1, *n* = 100        67.1, *n* = 98           Missing                    Missing
                                                                                                                                                                                                                                                                              IG: 100 pts\               IG:88 pts\                                                                                                            
                                                                                                                                                                                                                                                                              CG: 98 pts                 CG: 89 pts                                                                                                            

  Lai et al. (2011) \[[@B34-pharmacy-05-00028]\]              1 osteoporosis clinic, 1 hospital, Malaysia                                            Pts with postmenopausal osteoporosis                                                                                     198 pts:\                  177\                                       65.1, *n* = 100        67.1, *n* = 98           Missing                    Missing
                                                                                                                                                                                                                                                                              IG: 100 pts\               IG:88 pts\                                                                                                            
                                                                                                                                                                                                                                                                              CG: 98 pts                 CG: 89 pts                                                                                                            

  Lee et al. (2009) \[[@B35-pharmacy-05-00028]\]              3 Out-Patient Departments, 3 hospitals, Hong Kong                                      Pts with hyperlipidaemia                                                                                                 119 pts:\                  118 pts:\                                  63, *n* = 58           61, *n* = 60             34 (59), *n* = 58          26 (43), *n* = 60
                                                                                                                                                                                                                                                                              IG: 59 pts\                IG: 58 pts\                                                                                                           
                                                                                                                                                                                                                                                                              CG: 60 pts                 CG: 60 pts                                                                                                            

  Lim et al. (2004) \[[@B36-pharmacy-05-00028]\]              1 geriatric outpatient clinic, 1 hospital, Singapore                                   Elderly outpatients with risk factors of non-compliance                                                                  136 pts:\                  126 pts\                                   79.6, *n* = 64         80.5, *n* = 62           39%, *n* = 64              31%, *n* = 62
                                                                                                                                                                                                                                                                              IG: 68 pts\                IG: 64 pts\                                                                                                           
                                                                                                                                                                                                                                                                              CG: 68 pts                 CG: 62 pts                                                                                                            

  Magid et al. (2011) \[[@B37-pharmacy-05-00028]\]            3 healthcare systems, USA                                                              Pts with uncontrolled BP                                                                                                 338 pts:\                  283 pts\                                   65.1, *n* = 138        66.7, *n* = 145          67%, *n* = 138             63%, *n* = 145
                                                                                                                                                                                                                                                                              IG: 174 pts\               IG: 138 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 164 pts                CG: 145 pts                                                                                                           

  McCoy et al. (2012) \[[@B38-pharmacy-05-00028]\]            1 hospital, USA (entire hospital)                                                      Pts with an acute 0.5 mg/dL change in serum creatinine over 48 h and a nephrotoxic or renally cleared medication order   540 pts:\                  396 pts\                                   60.7, *n* = 200        58.3, *n* = 196          53%, *n* = 200             61%, *n* = 196
                                                                                                                                                                                                                                                                              IG: 262 pts\               IG: 200 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 278 pts                CG: 196 pts                                                                                                           

  Mergenhagen et al. (2012) \[[@B39-pharmacy-05-00028]\]      2 general medical units, 1 hospital, USA (entire hospital)                             Pts admitted for at least 24 h to one of the study units                                                                 359 ams:\                  218 ams:\                                  PharmG:\               PhysG:\                  PharmG:\                   PhysG:\
                                                                                                                                                                                                                                                                              111 ams (pharmacist)\      102 ams (pharmacist) 116 ams (physician)   68, *n* = 102          68, *n* = 116            100%, *n* = 102            98%, *N* = 116
                                                                                                                                                                                                                                                                              248 ams (physician)                                                                                                                              

  Morgado (2011) \[[@B40-pharmacy-05-00028]\]                 1 hospital care hypertension/dyslipidemia outpatient clinic, 1 hospital, Portugal      Pts with essential hypertension                                                                                          197 pts:\                  Missing                                    58.3, *n* = 99         60.7, *n* = 98           44 (45), *n* = 99          35 (35), *n* = 98
                                                                                                                                                                                                                                                                              IG: 98 pts\                                                                                                                                      
                                                                                                                                                                                                                                                                              CG: 99 pts                                                                                                                                       

  Murray et al. (2007) \[[@B41-pharmacy-05-00028]\]           1 ambulatory care practice, USA                                                        Pts with heart failure, low-income, ≥50 years                                                                            314 pts:\                  270 pts:\                                  61.4, *n* = 122        62.6, *n* = 192          39 (32), *n* = 122         65 (34), *n* = 192
                                                                                                                                                                                                                                                                              IG: 122 pts\               IG: 106 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 192 pts                CG: 164 pts                                                                                                           

  Sadik et al. (2005) \[[@B42-pharmacy-05-00028]\]            General medical wards, cardiology and medical outpatient clinics, 1 hospital, UAE      Pts with heart failure                                                                                                   221 pts\                   208 pts\                                   58.6, *n* = 104        58.7, *n* = 104          52 (50), *n* = 104         52 (50), *n* = 104
                                                                                                                                                                                                                                                                              IG: 109 pts\               IG: 104 pts\                                                                                                          
                                                                                                                                                                                                                                                                              CG: 112 pts                CG: 104 pts                                                                                                           

  Schnipper et al. (2006) \[[@B43-pharmacy-05-00028]\]        General medicine service, 1 hospital, USA                                              Pts discharged home                                                                                                      178 pts:\                  IG: 79, CG: 73 pts                         60.7, *n* = 92         57.7, *n* = 84           33%, *n* = 92              35%, *n* = 84
                                                                                                                                                                                                                                                                              IG: 92 pts\                                                                                                                                      
                                                                                                                                                                                                                                                                              CG: 84 pts                                                                                                                                       

  Spinewine et al. (2007) \[[@B44-pharmacy-05-00028]\]        1 acute Geriatric Evaluation and Management (GEM) unit, 1 hospital, Belgium            Pts aged ≥70 years                                                                                                       203 pts                    186 pts\                                   82.4, *n* = 96         81.9, *n* = 90           28%, *n* = 96              33%, *n* = 90
                                                                                                                                                                                                                                                                                                         IG: 96 pts\                                                                                                           
                                                                                                                                                                                                                                                                                                         CG: 90 pts                                                                                                            

  Stange et al. (2013) \[[@B45-pharmacy-05-00028]\]           1 medical Center, 1 hospital, Germany                                                  Pts with chronic hypertension, diabetes, and/or dyslipidemia                                                             240 pts\                   162 pts:\                                  64.4, *n* = 129        63.2, *n* = 108          81 (63), *n* = 129         90 (83), *n* = 108
                                                                                                                                                                                                                                                                              IG: 132 pts\               IG:89 pts\                                                                                                            
                                                                                                                                                                                                                                                                              CG: 108 pts                CG: 73 pts                                                                                                            

  Suppapitiporn et al. (2005) \[[@B46-pharmacy-05-00028]\]    1 endocrine Clinic, 1 hospital, Thailand                                               Pts with type 2 diabetes                                                                                                 360 pts:\                  Missing                                    61.4, *n* = 180        59.9, *n* = 180          59 (33), (*n* = 180)       64 (36), *n* = 180
                                                                                                                                                                                                                                                                              IG: 180\                                                                                                                                         
                                                                                                                                                                                                                                                                              IG 1 = 50 pts\                                                                                                                                   
                                                                                                                                                                                                                                                                              IG 2 = 50 pts\                                                                                                                                   
                                                                                                                                                                                                                                                                              IG 3 = 30 pts\                                                                                                                                   
                                                                                                                                                                                                                                                                              IG 4 = 50 pts\                                                                                                                                   
                                                                                                                                                                                                                                                                              CG: 180                                                                                                                                          

  Tsuyuki et al. (2004) \[[@B47-pharmacy-05-00028]\]          10 hospitals, Canada                                                                   Pts with heart failure                                                                                                   276 pts:\                  Missing                                    71, *n* = 140          72, *n* = 136            81 (58), *n* = 140         79 (58), *n* = 136
                                                                                                                                                                                                                                                                              IG: 140 pts\                                                                                                                                     
                                                                                                                                                                                                                                                                              CG: 136 pts                                                                                                                                      

  von Gunten et al. (2005) \[[@B48-pharmacy-05-00028]\]       General medical wards and intensive care units, 3 hospitals, Switzerland               Pts receiving antibiotic treatment                                                                                       1200 pts: IG; 600 pts,\    Missing                                    Different categories   Different categories     Different categories       Different categories
                                                                                                                                                                                                                                                                              CG: 600 pts\                                                                                                                                     
                                                                                                                                                                                                                                                                              IG1: 200 + 200 pts\                                                                                                                              
                                                                                                                                                                                                                                                                              IG2: 200 + 200 pts\                                                                                                                              
                                                                                                                                                                                                                                                                              CG: 200 + 200 pts                                                                                                                                

  Wu et al. (2006) \[[@B49-pharmacy-05-00028]\]               Specialist medical clinics, 1 hospital, Hong Kong                                      Non-compliant pts with polypharmacy                                                                                      442 pts:\                  Missing                                    71.2, *n* = 219        70.5, *n* = 223          108 (49), *n* = 219        107 (48), *n* = 223
                                                                                                                                                                                                                                                                              IG: 219 pts\                                                                                                                                     
                                                                                                                                                                                                                                                                              CG:223 pts                                                                                                                                       

  Zhang et al. (2012) \[[@B50-pharmacy-05-00028]\]            1 pediatric unit, 1 hospital, China                                                    Pediatric pts with nerve system disease, respiratory system disease or digestive system disease                          160 pts:\                  150 pts:\                                  Age groups             Age groups               43 (54), *n* = 80          44 (55), *n* = 80
                                                                                                                                                                                                                                                                              IG: 80 pts\                IG: 76 pts\                                                                                                           
                                                                                                                                                                                                                                                                              CG: 80 pts                 CG: 74 pts                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IG = Intervention group, CG = Control group.

pharmacy-05-00028-t002_Table 2

###### 

Description of study designs and intervention elements used in the included studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                      Intervention Elements   Study Design   Duration of Study (Intervention Period)/Monitoring   Post Intervention Follow-up                                                                                                                                                                                                                                                                       
  ----------------------------------------------------------- ----------------------- -------------- ---------------------------------------------------- ----------------------------- --- --- --- ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  Al Mazroui et al. (2009) \[[@B14-pharmacy-05-00028]\]       X                                                                                           X                             X           RCT                                                                                                                       Visits at 4 months, 8 months and 12 months                                                                                    No further follow-up

  Albsoul-Younes et al. (2011) \[[@B15-pharmacy-05-00028]\]   X                       X                                                                   X                             X           RCT                                                                                                                       Regular monthly visits to the clinic during 6 months                                                                          No further follow-up

  Barker et al. (2012) \[[@B16-pharmacy-05-00028]\]           X                       X                                                                   X                             X       X   RCT                                                                                                                       Home visits within 96 h of discharge, at 1 and 6 months                                                                       No further follow-up

  Bladh et al. (2011) \[[@B17-pharmacy-05-00028]\]            X                                                                                           X                             X       X   RCT                                                                                                                                                                                                                                                     6-month follow-up

  Chan et al. (2012) \[[@B18-pharmacy-05-00028]\]             X                       X                                                                   X                             X           RCT                                                                                                                       Intervention delivered at each clinic visit during 9 months after enrolment                                                   No further follow-up

  Chiu et al. (2008) \[[@B19-pharmacy-05-00028]\]             X \*\*                  X                                                                                                             Stratified RCT                                                                                                            The intervention was delivered monthly during 6 months                                                                        No further follow-up

  Chung et al. (2011) \[[@B20-pharmacy-05-00028]\]            X                       X                                                                   X                             X           Prospective controlled trial                                                                                              3 clinic visits and monthly telephone follow-ups during 24 months                                                             No further follow-up

  Crotty et al. (2004) \[[@B21-pharmacy-05-00028]\]                                                                                                       X                                     X   RCT                                                                                                                       1 interdisciplinary, cross-sectorial meeting at the long term care facility 14--28 days after discharge                       8-week follow-up

  Dedhia et al. (2009) \[[@B22-pharmacy-05-00028]\]                                                  X                                                    X                             X       X   Quasi-experimental pre--post study design                                                                                 .                                                                                                                             1-week and 30-day follow-up

  Gillespie et al. (2009) \[[@B23-pharmacy-05-00028]\]        X                                                                                           X                             X       X   RCT                                                                                                                       1 follow-up telephone 2 months after discharge                                                                                12-month follow-up

  Hammad et al. (2011) \[[@B24-pharmacy-05-00028]\]           X                       X                                                                   X                             X           RCT                                                                                                                       The intervention was delivered monthly during 6 months                                                                        No further follow-up

  Hellström et al. (2012) \[[@B25-pharmacy-05-00028]\]                                               X                                                    X                             X       X   Prospective, controlled study                                                                                             .                                                                                                                             6-month follow-up

  Jack et al. (2009) \[[@B26-pharmacy-05-00028]\]                                                    X                                                    X                             X       X   RCT                                                                                                                       1 follow-up phone call by clinical pharmacist 2 to 4 days after discharge                                                     30-day follow-up

  Jackson et al. (2004) \[[@B27-pharmacy-05-00028]\]          X                                                                                                                             X   X   Open-label RCT                                                                                                            4 home visits by clinical pharmacist on alternate days after discharge                                                        90-day follow-up

  Jacobs et al. (2012) \[[@B28-pharmacy-05-00028]\]           X                                                                                           X                             X       X   Prospective, randomized, clinical practice study                                                                                                                                                                                                        12-month follow-up

  Jarab et al. (2012a) \[[@B29-pharmacy-05-00028]\]           X                       X                                                                                                             RCT                                                                                                                                                                                                                                                     6-month follow-up

  Jarab et al. (2012b) \[[@B30-pharmacy-05-00028]\]           X                                                                                           X                             X           RCT                                                                                                                       8-week telephone follow-up call by clinical pharmacist                                                                        6-month follow-up

  Kirwin et al. (2010) \[[@B31-pharmacy-05-00028]\]                                                                                                       X                                     X   RCT                                                                                                                                                                                                                                                     30-day follow-up

  Kripalani et al. (2012) \[[@B32-pharmacy-05-00028]\]        X                       X              X                                                    X                             X       X   RCT                                                                                                                       1 telephone follow-up 1-4 days after discharge                                                                                30-day follow-up

  Lai et al. (2013) \[[@B33-pharmacy-05-00028]\]              X                       X                                                                   X                                         RCT                                                                                                                       Monthly follow-up via telephone calls for the first 6 months, then every 3 months until month 12                              No further follow-up

  Lai et al. (2011) \[[@B34-pharmacy-05-00028]\]              X                       X                                                                   X                                         RCT                                                                                                                       Monthly follow-up via telephone calls for the first 6 months, then every 3 months until month 12                              No further follow-up

  Lee et al. (2009) \[[@B35-pharmacy-05-00028]\]              X                       X                                                                   X                             X           RCT                                                                                                                       A telephone follow-up every 4 weeks and a follow-up interview on the date of the following physician visit within 16 weeks.   No further follow-up

  Lim et al. (2004) \[[@B36-pharmacy-05-00028]\]              X                       X                                                                   X                             X           RCT                                                                                                                                                                                                                                                     2-month follow-up

  Magid et al. (2011) \[[@B37-pharmacy-05-00028]\]            X                       X                                                                   X                             X       X   RCT                                                                                                                       6-month follow-up                                                                                                             No further follow-up

  McCoy et al. (2012) \[[@B38-pharmacy-05-00028]\]                                                                                                        X                             X           Randomized clinical trial                                                                                                                                                                                                                               No follow-up

  Mergenhagen et al. (2012) \[[@B39-pharmacy-05-00028]\]                                             X                                                                                              Quasi-experimental study. Subgroup analysis of a prospective, nonrandom, analytic cohort study with concurrent controls                                                                                                                                 1-month follow-up

  Morgado (2011) \[[@B40-pharmacy-05-00028]\]                 X                                                                                           X                             X           RCT                                                                                                                       3, 6 and 9-month follow-up                                                                                                    No further follow-up

  Murray et al. (2007) \[[@B41-pharmacy-05-00028]\]           X                                                                                           X                             X       X   RCT                                                                                                                       A pharmacist provided a 9-month multilevel intervention                                                                       3-month follow-up

  Sadik et al. (2005) \[[@B42-pharmacy-05-00028]\]            X                                                                                           X                             X       X   RCT                                                                                                                       Clinic visits at 3, 6, 9 and 12 months                                                                                        No further follow-up

  Schnipper et al. (2006) \[[@B43-pharmacy-05-00028]\]        X                       X              X                                                    X                             X       X   RCT                                                                                                                       A follow-up telephone call 3 to 5 days after discharge                                                                        30-day follow-up

  Spinewine et al. (2007) \[[@B44-pharmacy-05-00028]\]        X                                                                                           X                             X       X   RCT                                                                                                                                                                                                                                                     1 month, 3 months, and 1 year follow-up

  Stange et al. (2013) \[[@B45-pharmacy-05-00028]\]                                                                                                       X                             X       X   Prospective, semi-randomized study                                                                                                                                                                                                                      6-week follow-up

  Suppapitiporn et al. (2005) \[[@B46-pharmacy-05-00028]\]    X                       X                                                                                                             RCT                                                                                                                       Follow-up visits at 3 and 6 months                                                                                            No further follow-up

  Tsuyuki et al. (2004) \[[@B47-pharmacy-05-00028]\]          X                       X                                                                                                             Mixed design - partly RCT:\                                                                                               Follow-up at 2 weeks, 4 weeks, then monthly for 6 months after discharge                                                      No further follow-up
                                                                                                                                                                                                    Stage 1: In-hospital intervention in all patients\                                                                                                                                                                                                      
                                                                                                                                                                                                    Stage 2: randomized trial.                                                                                                                                                                                                                              

  von Gunten et al. (2005) \[[@B48-pharmacy-05-00028]\]                                                                                                   X                             X           Pre-post study. Randomised at hospital level                                                                                                                                                                                                            No follow-up

  Wu et al. (2006) \[[@B49-pharmacy-05-00028]\]               X                       X                                                                                                             RCT                                                                                                                       6-8 telephone calls and a finalizing visit during a 2-year follow-up                                                          No further follow-up

  Zhang et al. (2012) \[[@B50-pharmacy-05-00028]\]            X                                                                                           X                             X           RCT                                                                                                                       Patients were usually interviewed on phone when discharge drugs were half finished                                            2-week follow-up
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Patient counselling/education covers a large variety of activities including discharge counselling, patient education regarding medication and lifestyle etc. These activities are, however, often vaguely described and are consequently difficult to further categorise. \*\* Group education of patients.
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###### 

Outcome measures used in the included studies. The numbers in the cells are reference numbers.

  Measure                                                                                                                            Primary Outcome   Secondary Outcome   Total                                     
  ---------------------------------------------------------------------------------------------------------------------------------- ----------------- ------------------- ------------------------ ---------------- -----
  **Medication regimen characteristics**                                                                                                                                                                             
  Unnecessary drug use                                                                                                                                                                              44               1
  Duration of antibiotic treatment                                                                                                                                                                  48               1
  Composite score (dose, frequency and indication)                                                                                                                         36                                        1
  Unplanned cessation of warfarin                                                                                                                                                                   27               1
  Medication regimen intensity                                                                                                                                             37                                        1
  Medication complexity                                                                                                              45 ^B^                                                                          1
  Drug specific quality indicators                                                                                                                                                                  17               1
  72-h medication-prescribing risk score                                                                                                                                                            39               1
  Medication appropriateness index (MAI)                                                                                             19, 44                                                                          2
  Beers criteria                                                                                                                                       44                                                            1
  Assessing Care of Vulnerable Elders (ACOVE) underuse                                                                               44                                                                              1
  Medication discrepancies                                                                                                                                                                          43               1
  The number of clinically important medication errors per patient during the first 30 days after hospital discharge                                   32                                                            1
  Time to provider modification or discontinuation of targeted nephrotoxic or renally cleared medications                                                                                           38               1
  Medication beliefs                                                                                                                                                       29                                        1
  **Adherence to medication**                                                                                                                                                                                        
  Medication adherence/compliance self-reported (no validated tool)                                                                  50                                    14, 36, 40, 42                            5
  Medication adherence/compliance self-reported "Medication Adherence Rating Scale" (MARS-D)                                                           45 ^B^                                                        1
  Medication adherence/compliance self-reported (4-item Morisky Scale)                                                                                                     29, 30                                    2
  Medication adherence/compliance objectively assessed                                                                               41                47                  18                       37               4
  Medication adherence/compliance self-reported and objectively assessed                                                             34 ^A^                                49                       43               3
  Persistence                                                                                                                                          34 ^A^                                                        1
  **Adherence to guidelines**                                                                                                                                                                                        
  British National Formulary                                                                                                                                               14                                        1
  Lifestyle advice adherence                                                                                                                                               14, 42                                    2
  Adherence to guidelines                                                                                                                                                                           48               1
  Adherence to screening for retinopathy, neropathy, and microalbuminuria                                                                                                  28                                        1
  Annual (LDL-C) testing                                                                                                                                                                            31               1
  Annual urine microalbumin testing                                                                                                                                                                 31               1
  Rates of pneumococcal vaccination                                                                                                                                                                 31               1
  Change in rates of semiannual A1c testing from baseline to 30-day follow-up                                                                          31 ^B^                                                        1
  Frequency of primary care providers' follow-up within 30 days of discharge                                                                                               26                                        1
  Annual eye exam                                                                                                                                                          31                                        1
  **Adverse drug events/reactions**                                                                                                                                                                                  
  ADE (total)                                                                                                                                                              39                       21, 43           3
  Potential adverse drug events                                                                                                                                                                     32               1
  Potential Acute kidney injury (AKI) ADEs                                                                                                             38 ^A^                                                        1
  Acute kidney injury (AKI) related ADEs                                                                                                               38 ^A^                                                        1
  Preventable ADEs                                                                                                                   43 ^B^                                                                          1
  ADEs from admission prescribing errors                                                                                                                                   39                                        1
  Clinically important ADEs                                                                                                                                                                         32               1
  Adverse drug reactions                                                                                                                                                                            50               1
  Residual ADRs at month 2                                                                                                                                                 36                                        1
  **Laboratory measures**                                                                                                                                                                                            
  HbA1c                                                                                                                              14, 30 ^B^                            18, 28, 46               19, 31           7
  Fasting blood glucose                                                                                                                                                    30, 46                   19, 24           4
  Postprandial blood glucose                                                                                                                                                                        19               1
  Total cholesterol                                                                                                                                                        14, 20, 30, 35           19               5
  HDL                                                                                                                                                                      14, 35                   18, 20, 24, 30   6
  LDL                                                                                                                                35 ^B^                                14, 18, 19, 20, 28, 30   31               8
  Triglycerides                                                                                                                                                            14, 19, 20, 24, 30, 35   18               7
  The achievement of a therapeutic INR value on day 8 after discharge                                                                27                                                                              1
  \% patients achieving the ATP III LCL-C goal at the end of the study                                                               20                                                                              1
  Urinary albumin-to-creatinine ratio (ACR)                                                                                                                                                         18               1
  **Clinical measures/assessment by physicians**                                                                                                                                                                     
  BP                                                                                                                                                                       14, 15, 19, 24, 30       18, 31, 42       8
  Systolic BP                                                                                                                        40                                                             28               2
  Diastolic BP                                                                                                                                                             28, 40                                    2
  BP control                                                                                                                                                               40                                        1
  Achieving BP goals                                                                                                                                                       15                       37               2
  Pulse                                                                                                                                                                                             42               1
  Waist circumference                                                                                                                                                                               24               1
  Body weight                                                                                                                                                                                       24, 42           2
  BMI                                                                                                                                                                      14                       18, 30           3
  Symptoms                                                                                                                                                                                          42               1
  Bone turnover markers (BTMs)                                                                                                                         34 ^A^                                                        1
  Clinical status according to primary physician                                                                                                                                                    36               1
  2-min walk test                                                                                                                                                          42                                        1
  Forced vital capacity (FVC) measured by spirometer                                                                                                                       42                                        1
  Bleeding events 3 months after discharge                                                                                           27                                                                              1
  Falls                                                                                                                                                                                             21               1
  Framingham prediction scores                                                                                                                                             14                                        1
  Change in coronary heart disease (CHD) risk                                                                                        18                                                                              1
  Changes in stroke risk                                                                                                                                                   18                                        1
  Shift from a status of MS to no MS                                                                                                                                       24                                        1
  Worsening mobility                                                                                                                                                                                21               1
  Worsening behaviours                                                                                                                                                                              21               1
  Increased confusion                                                                                                                                                                               21               1
  Worsening pain                                                                                                                                                           21                                        1
  **Resource utilization**                                                                                                                                                                                           
  Length of stay (LOS) in hospital                                                                                                                                         47, 49, 50               48               4
  *Cardiovascular-related* LOS                                                                                                                                             47                                        1
  Physician visits                                                                                                                                                                                  47               1
  *Cardiovascular-related* Physician visits                                                                                                                                                         47               1
  Emergency department visits/casual department visits                                                                               23                                                             47, 49           3
  Emergency department visits (within 3 days)                                                                                                                              22                                        1
  Emergency department visits (within 30 days)                                                                                                                             22                                        1
  Emergency visits up to 12 months after discharge                                                                                                                                                  44               1
  *Cardiovascular-related* Emergency room visits                                                                                                                           47                                        1
  Time to emergency department revisits after discharge                                                                                                25 ^A^                                                        1
  Hospital readmission/hospital admission                                                                                            23                                    49                       44, 47, 50       6
  30 day readmission rate                                                                                                            22 ^B^                                                                          1
  Drug-related readmissions                                                                                                          23                                                                              1
  Unplanned readmission                                                                                                                                                                             27               1
  *Cardiovascular-related* Hospital readmissions                                                                                                                                                    47               1
  Readmissions to hospital due to anticoagulant-related complications within 90 days of initial discharge                                              27                                                            1
  Number of all cause and CHF hospitalization within 6 months of enrolment                                                                             16 ^A^                                                        1
  Number of CHF hospitalization within 6 months of enrolment                                                                                           16 ^A^                                                        1
  Days of all cause and CHF hospitalization within 6 months of enrolment                                                                               16 ^A,C^                                                      1
  Days of non-CHF-hospitalization within 6 months of enrolment                                                                                                             16                                        1
  Combination of emergency department visits and hospital readmissions                                                                                                     21                                        1
  Emergency department visits and hospitalizations within 30 days of discharge                                                       26                                                                              1
  Preventable medication related emergency department visits or readmissions                                                                                               43                                        1
  Exacerbations requiring emergency department care or hospital admission                                                            41                                                                              1
  The combined rate of post-discharge hospital revisits or death (ED visit, hospitalization or death)                                                                                               25               1
  Health care utilization (scheduled and unscheduled office visits, urgent care and ED visits, and hospital admissions)                                                                             43               1
  Costs                                                                                                                                                                                                              
  Costs                                                                                                                                                                    23, 26, 47                                3
  Total direct costs                                                                                                                                                       41                                        1
  Cost of antibiotic treatment                                                                                                                                                                      48               1
  Cost of drugs and hospitalization                                                                                                                                                                 50               1
  *Cardiovascular-related* Cost                                                                                                                                            47                                        1
  Cost-effectiveness                                                                                                                                                       18                                        1
  Cost avoidance                                                                                                                                                           36                                        1
  Mortality                                                                                                                                                                                                          
  Mortality (general)                                                                                                                                                                               23, 27, 44       3
  Mortality within 6 months of enrolment                                                                                                               16 ^A^                                                        1
  Time from randomisation to death from any causes                                                                                   49                                                                              1
  Event-free survival                                                                                                                                                                               25               1
  Quality of Life/Health related quality of life                                                                                                                                                                     
  Short form 36 (SF 36)                                                                                                                                                    14, 16, 42               16, 42           5
  Short form 12 (SF 12)                                                                                                                                                                             45               1
  EuroQol 5 dimension (EQ-5D)                                                                                                                          17 ^B^                                                        1
  Self-rated global health                                                                                                                                                 17                       17               2
  Assessment of quality of life (AQoL)                                                                                                                                                              16               1
  Minnesota living with heart failure questionnaire (MLHF)                                                                           42                                                                              1
  St George Respiratory Questionnaire (SGRQ)                                                                                                           29 ^B^                                                        1
  Chronic Heart Failure Questionnaire                                                                                                                                                               41               1
  Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO)                                                                                     33                                        1
  Patient knowledge                                                                                                                                                                                                  
  Patient medication knowledge                                                                                                       36                                    14, 18                   42               4
  COPD knowledge                                                                                                                                                           29                                        1
  Patients' knowledge of target BP values and of hypertension risks                                                                                                        40                                        1
  Malaysian Osteoporosis Knowledge Tool (MOKT)                                                                                                                             33                                        1
  Satisfaction and perception                                                                                                                                                                                        
  Satisfaction with information about medications                                                                                                                                                   44, 45           2
  Patient satisfaction with pharmacy services                                                                                                                              41                                        1
  Osteoporosis Patient Satisfaction Questionnaire (OPSQ)                                                                                                                   33                                        1
  Satisfaction with hospitalization and discharge processes                                                                                                                                         43               1
  Coleman's Care Transition Measures                                                                                                                                       22                                        1
  Patient perception (perception of severity of illness, usefulness of treatment and appropriateness of the number of medications)                                                                  36               1
  Other                                                                                                                                                                                                              
  Self-perceived health status                                                                                                                                             22                                        1
  Identification of index discharge diagnosis                                                                                                                              26                                        1
  Identification of primary care provider name                                                                                                                             26                                        1
  Self-reported preparedness for discharge                                                                                                                                 26                                        1
  Self-care activities (Diabetes Self-Care Activities questionnaire)                                                                                                       30                                        1
  Total                                                                                                                              26                16                  96                       78               216

^A^: Sample size calculation missing for: 15, 16, 19, 24, 25, 28, 33, 34, 37, 38, 39, 46, 48; ^B^: Sample size not achieved for: 17, 22, 29, 30, 31, 35, 43, 45; ^C^: Difference in favour of control group.
